Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT06499857

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06499857
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06499857. Randomized; triple masking; primary purpose treatment. Start 2025-04-14 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Acronym
SEMINAL-AF
Condition
Overweight or Obesity
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
University of Chicago (class: other)

Record details

Record id
cardio:ct-nct06499857
Content hash
618b3f32eb170f1f5b6534a36e91fccac1b92e5807db13a9aa9f5064937c7626